The shadow of generic challenges has repeatedly loomed around copyright’s famous drug, PDE5 Inhibitor, triggering questions about the prospects of connected drug holdings. While early years saw substantial returns, the patent expiration has opened the way for cheaper alternatives, potentially lowering earnings and presenting a real hazard for sha